首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Blood science

缩写:

ISSN:2543-6368

e-ISSN:2543-6368

IF/分区:3.6/Q2

文章目录 更多期刊信息

共收录本刊相关文章索引286
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Yujia Zhao,Hexiao Zhang,Qiuyan Han et al. Yujia Zhao et al.
Keloids, characterized by excessive collagen deposition and recurrence, pose significant therapeutic challenges due to limited mechanistic understanding. Mesenchymal stem cells (MSCs) exhibit potential for keloid management, but their preci...
Yu Zhang,Qiuju Huang,Yawen Zhang et al. Yu Zhang et al.
Long non-coding RNAs (lncRNAs) play a crucial role in normal and dysregulated hematopoiesis. However, the functional repertoire of lncRNAs across various hematopoietic cell types remains elusive. In this study, we constructed a comprehensiv...
Trasha Shetty,Anshuman Darbari Trasha Shetty
The demand for homologous blood transfusions has reached an unprecedented level, driven by a declining donor population and the ever-increasing need for blood products. While significant advancements have been made in medical equipment and ...
Chunhui Xu,Ren Lin,Ye Bai et al. Chunhui Xu et al.
Infections are frequent complications in patients with hematological disorders, and pathogen diagnosis remains challenging. Metagenomic next-generation sequencing (mNGS) is an unbiased high-throughput technology that has been widely applied...
Shanshan Zhang,Haina Wang,Xuehong Zhang et al. Shanshan Zhang et al.
Due to the limited availability of effective treatment therapies, patients with refractory and relapsed acute myeloid leukemia (AML) often have poor prognoses. Therefore, identifying new therapeutic targets to improve the treatment landscap...
Linjuan Wang,Shaowei Qiu Linjuan Wang
Chimeric antigen receptor (CAR) T-cell therapy is an epoch-making immunotherapy for the treatment of relapsed or refractory (r/r) blood tumors, as demonstrated by its successful implementation in r/r B cell-derived malignancies. However, re...